000 | 01991 a2200529 4500 | ||
---|---|---|---|
005 | 20250515215447.0 | ||
264 | 0 | _c20101122 | |
008 | 201011s 0 0 eng d | ||
022 | _a1524-4733 | ||
024 | 7 |
_a10.1111/j.1524-4733.2010.00709.x _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aBojke, Laura | |
245 | 0 | 0 |
_aEliciting distributions to populate decision analytic models. _h[electronic resource] |
260 |
_bValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research _cAug 2010 |
||
300 |
_a557-64 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_aAnti-Inflammatory Agents, Non-Steroidal _xeconomics |
650 | 0 | 4 |
_aAntibodies, Monoclonal _xeconomics |
650 | 0 | 4 |
_aAntirheumatic Agents _xeconomics |
650 | 0 | 4 |
_aArthritis, Psoriatic _xdrug therapy |
650 | 0 | 4 | _aCost-Benefit Analysis |
650 | 0 | 4 | _aDecision Support Techniques |
650 | 0 | 4 | _aDisease Progression |
650 | 0 | 4 | _aEtanercept |
650 | 0 | 4 | _aFeasibility Studies |
650 | 0 | 4 | _aHealth Care Costs |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aImmunoglobulin G _xeconomics |
650 | 0 | 4 | _aInfliximab |
650 | 0 | 4 | _aModels, Economic |
650 | 0 | 4 | _aModels, Statistical |
650 | 0 | 4 |
_aPalliative Care _xeconomics |
650 | 0 | 4 | _aProbability |
650 | 0 | 4 |
_aProgram Evaluation _xeconomics |
650 | 0 | 4 | _aQuality of Life |
650 | 0 | 4 | _aQuality-Adjusted Life Years |
650 | 0 | 4 |
_aReceptors, Tumor Necrosis Factor _xtherapeutic use |
650 | 0 | 4 | _aUncertainty |
650 | 0 | 4 | _aUnited Kingdom |
700 | 1 | _aClaxton, Karl | |
700 | 1 | _aBravo-Vergel, Yolanda | |
700 | 1 | _aSculpher, Mark | |
700 | 1 | _aPalmer, Stephen | |
700 | 1 | _aAbrams, Keith | |
773 | 0 |
_tValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research _gvol. 13 _gno. 5 _gp. 557-64 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1524-4733.2010.00709.x _zAvailable from publisher's website |
999 |
_c19706812 _d19706812 |